Eqitx appoints chief executive officer
Wednesday, 01 September, 2004
Melbourne-based Equitx (ASX:EQX) has appointed former Agenix vice president Sue Parry-Jones as chief executive officer.
“Sue’s experience in new product development and commercialisation at a number of large pharmaceutical companies including Schering-Plough and Bristol-Myers Squibb, together with her biotechnology industry experience at Agenix and Amgen, have given her an ideal mix of skills to progress the development of our VacTX novel vaccine and ZingoTX Gingerol projects,” said Eqitx Chairman Mr Sol Majteles in a statement. Parry-Jones was most recently vice president of Molecular Diagnostic Imaging at Agenix.
Heart muscle regeneration genes mapped
Researchers have uncovered insights into how stem cells develop and mature into heart muscle...
The cause of 2022's mpox outbreak revealed
Researchers have discovered that the strain of mpox behind the 2022 outbreak was a weakened form...
New gene therapy treats liver disorder in growing children
Researchers have developed a genome-editing approach that repairs a faulty gene directly at its...
